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We describe a case of renal papillary necrosis in a middle-aged female with sickle cell trait who presented with
gross hematuria. We wish to highlight this case for several reasons. Sickle cell trait is often viewed as a benign
condition despite the fact that it is associated with significant morbidity such as renal papillary necrosis
and renal medullary carcinoma. Appropriate evaluation needs to be undertaken to promptly diagnose renal
papillary necrosis and differentiate it from renal medullary carcinoma as this can result in deadly con-
sequences for patients. CT urography has emerged as a diagnostic study to evaluate hematuria in such
patients. We review the pathophysiology, diagnosis, and management of renal papillary necrosis in patients
with sickle cell trait.
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A
42-year-old African American woman with a
history of sickle cell trait (SCT) was admitted to
the hospital for painless gross hematuria with
the passage of clots for 3 weeks. She also complained of
fatigue, dizziness, and general malaise. She denied abdom-
inal pain, dysuria, or fever. She had a remote history of
similar presentation 20 years ago that resulted in right-
sided partial nephrectomy. It was performed in an outside
hospital and medical records were not available. She re-
ported no other significant medical history and was not
taking any medications at home. Familyand social history
was unremarkable.
On physical examination, the patient had stable vital
signs with a blood pressure of 120/70 mm Hg, heart rate
90/min, and temperature of 98.48F. She appeared com-
fortable but with marked pallor. Her abdomen was soft,
non-tender, non-distended, and revealed no costoverteb-
ral angle tenderness. The rest of the physical examination
was unremarkable.
Laboratory data revealed hemoglobin of 5.7 g/dl,
hematocrit 17.2%, platelets 317 K/ml, INR 0.93., and
creatinine of 0.9 mg/dl. Other pertinent laboratory values
showedbilirubinof1.1,LDHof139U/L,andhaptoglobin
of 90 mg/dl. Hemoglobin electrophoresis demonstrated
Hb A 74.7%, Hb A2 2.9%, Hb F 0.4%, and Hb S 22%, but
itwasdrawnaftertransfusion.Urinalysisshowednumerous
red blood cells (RBCs), 2 protein, and 25 WBC/HPF.
Peripheral smear, vasculitiswork up, or urine culture were
not performed. Initial CT scan of abdomen and pelvis
revealed hyper dense material in collecting system of right
kidney extending into renal pelvis but no aneurysm or
calculus was demonstrated. Later patient underwent re-
nal angiography, which demonstrated normal arterial
anatomy. She also underwent CTurography that revealed
a filling defect within the pyramid of the lower pole of the
right kidney representing papillary necrosis as demon-
strated in Fig. 1.
The patient was managed conservatively during the
hospital course. She was transfused with 3 units of blood
and blood counts remained stable after transfusion. In the
beginning, our differential diagnosis was broad, including
renal papillary necrosis, IgA nephropathy, bladder cancer,
and renal medullary carcinoma. But the diagnosis was
narrowed down to renal papillary necrosis after CT uro-
graphy was performed. Patient was started on sodium
bicarbonate infusion along with aggressive hydration and
diuretics. After 3 days of treatment, her hematuria had
completelyresolvedandshewasdischargedhomeinstable
condition.
Renal papillary necrosis and sickle cell trait
SCT is a carrier state of sickle cell disease with one copyof
normal beta globulin gene and one copy of sickle variant
gene-producing heterozygous HbAS (1). SCT is estimated
to have prevalence of 300 million worldwide, mostly con-
centrated in Africa, Middle East, and Mediterranean
region (2). In the United States, the prevalence of SCT
is around 810% in African American population (3).
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increased mortality in individuals (4), it has been asso-
ciated with several complications (2).
A number of abnormalities have been reported in SCT,
including renal medullary carcinoma, papillary necrosis,
thromboembolic events, and hyposthenuria (5, 6). Renal
complications are listed in Table 1 (7, 8). Our discussion
will be limited to renal papillary necrosis.
Renal papillary necrosis is frequently associated with
sickle cell disease, but it is not uncommon in SCTas well.
It has been usually associated with diabetes, analgesic
nephropathy, chronic pyelonephritis, and renal tuber-
culosis. Renal papillary necrosis is usually precipitated by
some factors such as intense exercise, dehydration, and
taking NSAIDs. In our patient, none of these factorswere
present. To date no comparative data exist with regard to
the distribution and frequency of occurrence of renal
papillary necrosis among persons with SCT, hemoglobin
SC, and thalassemias (5, 9); however, there have been case
reports on hemoglobin SC (9, 10) but none to date on
thalassemia unless associated with a sickling hemoglobin
(Sb
) (11).
Pathophysiology
Papillary necrosis results from obstruction of the vasa
recta producing ischemia and micro infarction of medul-
lary region of the kidneys (12). Polymerization of the
RBCs in the vasa recta of the renal medulla is the main
trigger for renal papillary necrosis. Numerous factors are
involved in initiating the sickling of RBCs including
hypoxia, hypertonicity, and acidosis (13). Once sickling
starts it leads to increased blood viscosity and decreased
blood flow to medulla, which ultimately results in micro
infarction of vasa recta causing papillary necrosis. The
extent of polymerization of RBCs depends upon the
concentration of HbS (11).
Clinical features
The clinical presentation varies from painless gross hema-
turia to acute condition with pain, fever, and obstructive
urinary symptoms (14, 15). Hematuria is by far the most
important clinical feature. It usually manifests in the age
group between 3040 years and there seems to be no sex
predominance (16). Any patient with SCT, who presents
with hematuria, needs a thorough clinical investigation
especially in young patients because renal medullary
carcinoma can also presents in a similar fashion. Renal
medullary carcinoma is a rare, aggressive fatal tumor,
which presents in young patients with SCT (6). Because
renal medullary cancer is very rare, there is no epidemio-
logical data available, but according to one report in 2003,
there are 55 cases of renal medullary cancer that were
reported in literature (6).
Diagnosis
Renal papillary necrosis should be in the differential
diagnosisinanySCTpatient whocomesinwithhematuria.
Imaging studies are the mainstay of diagnosing this
condition. Intravenous pyelogram has been traditionally
used for establishing the diagnosis but it is now largely
replaced with CTurography because of its high sensitivity
and specificity (17, 18). CT urography is also superior to
other imaging studies because of its ability to diagnose
papillary necrosis in early stages (19) but more studies are
required for comparison between IVP, ultrasound, and
CT urography. In all reported cases, there was no bio-
psy performed and renal angiogram is not required for
diagnosis. In SCT, the most common abnormality on
urinalysis is microscopic hematuria that can also be
macroscopic. However, there is limited data on the pre-
valence of these findings. The most common findings on
urinalysis of patients with sickle cell disease is proteinuria
as this proteinuria occurs in 2030% of patients with
sickle cell disease. Hemoglobinuria and RBC casts can
also occur. Additionally, there is decreased concentrating
ability with urine osmolarity of 400450 mOsm/kg under
water deprivation (12). Hemoglobin electrophoresis is not
required for diagnosis nor is there any renal correlation.
Management
Although there are no large studies done to standardize
the treatment of papillary necrosis secondary to SCT,
the underlying pathophysiology guides the treatment
Table 1. Renal complications of sickle cell trait
Renal medullary carcinoma
Renal papillary necrosis
Hyposthenuria
Hematuria
Fig. 1. Computerized tomography urography depicting blunt-
ing of renal calyx of right kidney (see arrow).
Uqba Khan et al.
2
(page number not for citation purpose)
Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25418 - http://dx.doi.org/10.3402/jchimp.v4.25418modalities. As mentioned earlier, papillary necrosis starts
with sickling of RBCs, which is itself affected by factors
like acidosis, hypertonicity, and hypoxia. If we can reduce
these factors then papillary necrosis can be contained.
Treatment options that have been utilized are listed in
the Table 2 (7, 15, 16). Initial management involves
conservative measures, as most of the cases of hematuria
are self-limiting. Patient should be started on hypotonic
fluids along with diuretics to increase the urine flow and
reduce the tonicity in the medullary interstitial area.
Hypotonic fluids correct dehydration and diuretics help
in increasing urinary flow. Sodium bicarbonate is also
used to alkalinize the urine, which reduces the acidosis,
but whether it prevents further necrosis is uncertain. In
some reports desmopressin (increases clotting by dose-
dependent increase in plasma factor VIII, and vWF) and
Epsilon-amino caproic acid (inhibits fibrinolysis by in-
hibiting plasmin activity) can be used to treat hematuria
in resistant patients (7, 2022). If all the aforementioned
measures fail, then invasive measures can be taken which
involve renal artery embolization and nephrectomy.
Conclusion
Renal papillary necrosis is a rare complication of SCT.
It should be considered in the differential diagnosis of
gross hematuria, especially in sickle cell patients, because
if it is not caught earlier it can lead to devastating com-
plications. Conservative measures should always be tried
first before attempting invasive procedures.
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Table 2. Management options for renal papillary necrosis
1 Bed rest and hydration
2 Hypotonic fluid resuscitation with diuretics
3 Sodium bicarbonate to reduce acidosis
4 Desmopressin
5 Epsilon-aminocaproic acid
6 Renal artery embolization or nephrectomy if conservative
measures fail to resolve hematuria.
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